SEARCH RESULTS

Biotechnology in France

Anindita BANERJEE - 08-avr.-2014 12:23:15
  Even though biotechnologies may be a recent sector of business activity, France has succeeded in developing real know-how that is gaining international recognition. When it comes to biotechnologies, the French are cutting edge. According to Leeme, the federation of French medical companies, today France numbers 388 biotechs in the health field in France. Biotech France, another French association for biotech companies, indicates that a third of these companies have been in existence for over 10 years. Yet the number of creations in this field is exponential. To get an idea, 50 companies were started in 2012. Unheard of! Proof that there is a real entrepreneurial effervescence when it comes to this research in France. Young start-ups for the most part, French biotechs are mainly Small Medium sized companies. Only 4% of them have over 100 employees. On average, they employ 22 people. As to the type of activity, most of the French companies specialized in human sciences with therapeutic products are concentrated on cancer treatments. “The French have developed a full-fledged know-how on cardio-vascular devices, infectious diseases, dermatology, blood diseases and for surgery,” explains Yves Germani, Ubifrance’s manager for the health sector in North America. French enterprises don’t just do research; they discover! Altogether, the French biotech industry generated 261 Million Euros in turnover in 2011, compared with 186 Million in 2010. As for companies on the stock market, they generate 369 Million Euros in turnover. Concerning the pipeline, the expression used to indicate the number of molecules being developed, France is 4rth, behind the United Kingdom, Germany, Switzerland and Israel. Quite a solid ranking, but which should nevertheless be improved. When their results are examined in detail, we see that depending on the stage of development, French companies create more products in the pre-clinic phase, in other words, all those that have been carried out before the clinical trial with patients, which is completely logical. Between the start of development on a new medicine, a molecule and its release on the market can sometimes take up to 10 years. Unfortunately, the consequence of this is that a number of products fall by the wayside. To be noted, however, is one undeniable fact: since 2008, French companies have sold more and more products. To put it another way, as Yves Germani points out, French companies don’t just do research; they discover!” An increase of 63% in investment Even more impressive than all the rest, French biotech companies tend to have smaller R&D budgets than their European and international competitors. Fortunately, the culture of venture capital is developing very quickly in this sector. To give the general picture, the funds raised by French biotechs have increased by 63,1% from 2009 to 2012, reaching 178 Million Euros. Since the year 2000, they have managed to raise 2.920 Billion Euros. Today, French companies are naturally turning towards international opportunities to find new partners and new financial leverage. The proof is that such Small Medium companies as Affilogic, MedinCell, Interactive Biosoftware, Imabiotech or even O4CP all have one thing in common: they all are reaching out with confidence to mature markets like the United States, Canada and Western Europe.  

World HAI Forum: Global Call to Action to Fight

Julien Compain - 12-août-2011 12:15:28
                                            World HAI Forum: Global Call to Action to Fight                                              Antibiotic Resistance Over 70 international experts in medicine, infectious diseases, microbiology and epidemiology, from every continent, gathered at the Fondation Mérieux’s Conference Center for the third edition of the World HAI Forum on healthcare-associated infections, a bioMérieux initiative. Forum participants call upon national and international health authorities and policy makers, the medical and veterinary communities, Industry, and the general public to take action to avoid an impending public health catastrophe caused by the emergence and spread of bacteria that are resistant to all antibiotics. While research to discover novel antibiotics has slowed to a virtual standstill, bacterial resistance has increased due to the massive use and misuse of antibiotics, not only for human health, but also for animals. The treatment of certain common infections is becoming difficult and the success of immunosuppressive therapies and surgical interventions (organ transplants, cardiac surgery), which are associated with a high risk of bacterial infection, could be compromised. To the Forum experts, the emergence of pan-resistant NDM-1 bacteria and epidemic of multidrug-resistant E. coli infections currently in Europe should be taken as a major public health warning, indicating that a new era of antimicrobial resistance has begun. This must lead to a global awakening: the protection of antibiotics has now entered the sphere of sustainable development. In a continuation of calls to action and proposals made by major national and international organizations (WHO, ECDC, IDSA, CDC, etc.), the Forum’s participants identified priority action areas to fight bacterial resistance and recommended 12 very concrete actions to be implemented, in the short to mid-term, to effectively address this serious problem. Priority actions for policy makers and health authorities -          For animals, stop the administration of antibiotics used in human medicine and limit antibiotics to therapeutic use only. It is imperative to reserve the most important classes of antibiotics for humans. -          Banish, in all countries, the use of antibiotics as growth promoters in animal feed. -       Regulate the sale of antibiotics for use in human medicine and prohibit over-the-counter sales worldwide. -       Have international organizations (WHO, European Union) develop a charter on good antibiotic stewardship and have all the ministries of health worldwide sign it and commit to respecting it.  Priority actions for the human and veterinary healthcare communities -       Establish standardized, universal surveillance of antibiotic use and resistance and monitor the emergence and spread of new forms of bacterial resistance. -       Include, in the medical and veterinary school curricula, a solid training in bacterial resistance and the prudent use of antibiotics and establish on-the-job training programs for healthcare workers, taking into account the cultural specificities of each country. Priority actions for the general public -       Develop culturally sensitive awareness campaigns, targeted to the general public, explaining the importance of protecting antibiotics and using them only when absolutely necessary. -       Provide education about fundamental hygiene, such as handwashing to prevent the spread of infection. It is imperative to improve sanitation systems to eliminate resistant bacteria in wastewater. -       Include consumers in the development and implementation of action plans. Priority actions for lndustry -       Develop Point-of-Care and rapid diagnostic tests, which can be used at the patient’s bedside or the doctor’s office, to guide the prescription of antibiotics and avoid their prescription for viral infections. -       Stimulate research and development of novel antibiotics. -       Find new economic models, which reconcile public health interests with Industry needs for profitability. About the World HAI Forum To hear what experts discussed at the Forum: www.hai-forum.com For more information visit: www.bioMerieux.com/hai-resistance   Organized from June 27-29, the 3rd edition of the World HAI Forum was characterized by the exceptional geographical diversity of its participants, coming from 33 countries.  While most meetings focus on scientific developments retrospectively in an academic format, the World HAI Forum, which is held every two years, gives participating experts a chance to do prospective analysis of subjects that are not usually discussed. More time is devoted to sharing best practices, successes and failures in the fight against multidrug-resistant bacteria, as a basis for building effective action plans. A world leader in microbiology and a pioneer in resistance detection and susceptibility testing, bioMérieux works closely with healthcare professionals in the three key areas of Infection Control: Prevention, Surveillance and Intervention. Diagnostic tests are paramount to success in the fight against infections with resistant bacteria. As part of its commitment to fight HAIs and microbial resistance, bioMérieux has also held HAI symposia around the world over the past 3 years, in countries including the United States, Belgium, the Netherlands, Portugal, Spain, China, Japan, Korea, Colombia and Saudi Arabia. In India, bioMerieux has held six sessions of the HAI Forum across the Country, under the leadership of Dr. Chand Wattal - a recognized expert - with the active participation of leading Clinicians and Microbiologists. During the discussion experts highlighted the three main threats to public health globally and in India: Gram-negative organisms, which are multi-drug resistant as there are not many antibiotics to treat these organisms, common bacteria,  like Escherichia coli: (E. coli) are now producing enzymes which make the bacteria capable of de-activating all but the antibiotics that specialists reserve as a last line of, defense. Healthcare workers themselves may be contributing to the spread of infections by failing to get flu vaccinations and, in some countries, coming to work when they are ill rather than taking sick leave. Stress was laid on the need to ensure a continuous monitoring of infection, exchange of information and the adoption of a well defined policy for the rational use of antibiotics. About bioMérieux Advancing Diagnostics to Improve Public Health A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than150 countries through 39 subsidiaries and a large network of distributors. In 2010, revenues reached €1.357 billion with 87% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479). Other information can be found at www.biomerieux.com . Contacts    Media Relations      bioMérieux - Koren Wolman-Tardy - Tel: + 33 4 78 87 20 08    media@biomerieux.com   Pure Communications - Kathryn Cook  - Tel: + 1 910-509-3976   kathryn@purecommunicationsinc.com   Image Sept  - Laurence Heilbronn - Tel: + 33 1 53 70 74 64  lheilbronn@image7.fr   French Trade Commission -  Press Information: Deepika PRAKASH Press Officer French Trade Commission Embassy of France 2/50 E Shantipath, Chanakyapuri New Delhi 110021 Telephone: +91 11 43 19 63 51 Email: deepika.prakash@ubifrance.fr                                                                               
About
Sophie Clavelier, Country Head   Welcome to the French Trade Commission Business France in India!     Our key mission is to promote trade relations between France and India. We assist French- based companies seeking potential partners and new markets in India, while helping Indian businesses to identify potential French suppliers, commercial and technical partners.   In India, our 4 offices are located in business hubs, New Delhi, Mumbai, Bengaluru and Chennai. We have a dedicated multicultural team of 38 experts in the following growing sectors: Agrofood Industry Industry and Cleantech Lifestyle and Healthcare Tech & Services Our Trade Commission also has a Press office in charge of helping French companies to communicate in India as well as a Market Access Department enabling them to better understand and adjust to the Indian regulatory and fiscal framework. In

READ MORE

Facebook
Press area & Media Gallery
List of last comments

Bluestorage is a subsidiary of the Bollo...

Malcolm MESSIER | février 22, 2019

AdBGQi Thank you for this impressive rep...

best pron | janvier 29, 2018

pYktcT Well I definitely liked studying ...

just another | novembre 08, 2017

dv1KAR Say, you got a nice post.Thanks A...

best pron | septembre 20, 2017